carvedilol has been researched along with cyclosporine in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 15 (65.22) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Backman, U; Dimény, E; Fellström, B; Johnsson, C; Kaijser, M; Zezina, L | 1 |
| Csöllei, J; Salplachta, J; Strnadová, V | 1 |
| Ha, H; Ki, MS; Kim, HJ; Kim, YS; Park, J; Park, K | 1 |
| Moreno, AJ; Oliveira, PJ; Palmeira, CM; Rolo, AP | 1 |
| Antonello, A; Calò, L; Davis, PA; Giacon, B; Huber, W; Pagnin, E; Piccin, A; Riegler, P; Semplicini, A | 1 |
| Bartosíková, L; Necas, J; Salplachta, J | 1 |
| Chopra, K; Padi, SS | 1 |
| Ha, H; Kim, H; Kim, MS; Kim, YS; Lee, JH; Park, J; Park, K; Seo, J | 1 |
| Esteves, T; Moreno, AJ; Oliveira, PJ; Palmeira, CM; Rolo, AP | 1 |
| Bader, FM; Crompton, JA; Gilbert, EM; Hagan, ME | 1 |
| Biedunkiewicz, B; Chamienia, A; Rutkowski, B; Tylicki, L; Wojnarowski, K; Zdrojewski, Z | 1 |
| Serón, D | 1 |
| Amioka, K; Ejiri, M; Kushihara, H; Kuzuya, T; Nabeshima, T; Nitta, A | 1 |
| Alghorabi, AA; Estfanous, RS; Kabel, AM; Salama, SA | 1 |
1 review(s) available for carvedilol and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for carvedilol and cyclosporine
| Article | Year |
|---|---|
Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Carbazoles; Carvedilol; Cyclosporine; Drug Evaluation; Female; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Male; Membrane Proteins; Middle Aged; Nifedipine; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Postoperative Complications; Propanolamines; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta; Treatment Outcome; Tyrosine | 2002 |
Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients.
Topics: Albuminuria; Blood Pressure; Carbazoles; Carvedilol; Cyclosporine; Female; Humans; Kidney Function Tests; Kidney Transplantation; Losartan; Male; Middle Aged; Placebos; Propanolamines | 2006 |
20 other study(ies) available for carvedilol and cyclosporine
| Article | Year |
|---|---|
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Cyclosporine; Drug Interactions; Female; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Propanolamines; Vasodilator Agents | 1997 |
[Effect of Consupren, Carvedilol and BL-443 on the composition of lactate dehydrogenase in tissues of rats with cyclosporin nephropathy].
Topics: Adrenergic Antagonists; Animals; Antihypertensive Agents; Carbamates; Carbazoles; Carvedilol; Cyclosporine; Immunosuppressive Agents; Isoenzymes; Kidney Diseases; L-Lactate Dehydrogenase; Liver; Lung; Male; Muscle, Skeletal; Myocardium; Propanolamines; Rats; Rats, Wistar; Spleen | 2002 |
Effects of carvedilol alone and in the presence of cyclosporine A on the DNA synthesis of cultured vascular smooth muscle cells.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Cells, Cultured; Cyclosporine; DNA; Immunosuppressive Agents; Muscle, Smooth, Vascular; Propanolamines; Rats; Rats, Sprague-Dawley | 2002 |
Carvedilol reduces mitochondrial damage induced by hypoxanthine/xanthine oxidase: relevance to hypoxia/reoxygenation injury.
Topics: Adrenergic beta-Antagonists; Animals; Calcium; Carbazoles; Carvedilol; Cyclosporine; Hypoxanthine; Hypoxia; Male; Membrane Potentials; Mitochondria, Heart; Mitochondrial Swelling; Oxidative Stress; Oxygen Consumption; Propanolamines; Rats; Superoxides; Xanthine Oxidase | 2001 |
Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy.
Topics: Animals; Carbamates; Carbazoles; Carvedilol; Cyclosporine; Drug Therapy, Combination; Glomerulonephritis, Membranous; Isoenzymes; Kidney; L-Lactate Dehydrogenase; L-Lactate Dehydrogenase (Cytochrome); Male; Propanolamines; Rats; Rats, Wistar; Reference Values | 2002 |
Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol.
Topics: Animals; Antioxidants; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Cyclosporine; Disease Models, Animal; Drinking; Female; Immunosuppressive Agents; Kidney Diseases; Lipid Peroxidation; Male; Oxidative Stress; Propanolamines; Rats; Rats, Wistar; Urine | 2002 |
Effect of carvedilol alone or in the presence of cyclosporine on the migration of vascular smooth muscle cell of rat.
Topics: Angiotensin II; Animals; Carbazoles; Carvedilol; Cells, Cultured; Chemotaxis; Cyclosporine; Immunosuppressive Agents; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Propanolamines; Rats; Rats, Sprague-Dawley | 2003 |
Carvedilol inhibits the mitochondrial permeability transition by an antioxidant mechanism.
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Atractyloside; Calcium; Carbazoles; Carvedilol; Cyclosporine; Immunosuppressive Agents; In Vitro Techniques; Male; Mitochondria, Heart; Oxidative Stress; Permeability; Propanolamines; Proteins; Rats; Rats, Wistar; Sulfhydryl Compounds; tert-Butylhydroperoxide | 2004 |
The effect of beta-blocker use on cyclosporine level in cardiac transplant recipients.
Topics: Absorption; Adrenergic beta-Antagonists; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbazoles; Carvedilol; Cyclosporine; Drug Interactions; Heart Transplantation; Humans; Hypertension; Immunosuppressive Agents; Metoprolol; Propanolamines; Retrospective Studies | 2005 |
Management of cardiovascular risk in patients receiving calcineurin inhibitors--a case report.
Topics: Acenocoumarol; Amiodarone; Angioplasty; Calcineurin Inhibitors; Carbazoles; Carvedilol; Cyclosporine; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Immunosuppressive Agents; Indoles; Kidney Transplantation; Male; Middle Aged; Myocardial Infarction; Nitroglycerin; Postoperative Complications; Pravastatin; Prednisone; Propanolamines; Risk Factors; Tacrolimus; Treatment Outcome | 2006 |
Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Carbazoles; Carvedilol; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Immunosuppressive Agents; Injections, Intravenous; Intestinal Absorption; Male; Propanolamines; Rats; Rats, Wistar; Verapamil | 2007 |
Amelioration of cyclosporine-induced testicular toxicity by carvedilol and/or alpha-lipoic acid: Role of TGF-β1, the proinflammatory cytokines, Nrf2/HO-1 pathway and apoptosis.
Topics: Animals; Carvedilol; Cyclosporine; Heme Oxygenase (Decyclizing); Male; NF-E2-Related Factor 2; Rats; Signal Transduction; Temazepam; Testis; Thioctic Acid; Transforming Growth Factor beta1 | 2020 |